Lupin receives EIR from USFDA for its Goa manufacturing site, shares gain

Lupin said USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI), which means USFDA will not recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3GFIcmp
via IFTTT